JMP Securities Downgrades Cerus (CERS) to Market Underperform
More News related to CERS
- Cerus (CERS) Misses Q3 EPS by 4c
- Cerus Corporation Announces Third Quarter Financial Results
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Cerus to Release Third Quarter Results on October 29, 2009
- Cerus (CERS) To Present Phase III Trial Design On INTERCEPT to FDA On 11/16
More News related to Downgrades
- After-Hours Movers 11/10: BITS, GSB, OCNF, HOO Higher; TGIC, MCZ, STV, MBLX, EM Lower
- Trading Radar for 11/11: Macy's (M), Progressive (PGR), Advanced Auto Parts (AAP), Computer Sciences (CSC) Report
- Unusual 11 Mid-Day Movers 11/10: UPG, CSII, SGK, MEDQ Higher; RHIE, OPXT, PRKR, MBI Lower
- Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
- Notable Analyst Rating Changes 11/10: ADBE, ANN, FRPT, RAX Upgraded; ALU, CPST, PIKE, TRW Downgraded
JMP Securities downgrades Cerus (Nasdaq: CERS) from Market Perform to Market Underperform.
Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System.
Related Categories
DowngradesStocks Mentioned
+0.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
